Erythropoietin and sexual dysfunction

Lawrence, Ian; Price, David E.; Howlett, Trevor A.; Harris, Kevin; Feehally, J.; Walls, John

doi:10.1093/ndt/12.4.741

Cited by 52 publications

(37 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Erythropoietin therapy has been shown to improve sexual function in the male dialysis patients, with a direct effect upon endocrine function, as well as anemia. 14 Erythropoietin therapy was performed on 81% of HD patients in this study.…”

Section: Discussionmentioning

confidence: 99%

Significant decrease of the International Index of Erectile Function in male renal failure patients treated with hemodialysis

et al. 2002

View full text Add to dashboard Cite

In order to evaluate the erectile function in male renal failure patients treated with hemodialysis (HD), we investigated the International Index of Erectile Function (IIEF) in patients and healthy controls. The subjects were 174 male patients treated with HD, of whom 43 had diabetes mellitus (DM) and the remaining 131 patients did not have DM. The controls were 1133 healthy males. We evaluated the prevalence of erectile dysfunction (ED) using the erectile function (EF) score, which is one of the five domains of the IIEF, in each age group (upto 39 y old, 40 -49 y old, 50 -59 y old, 60 -69 y old). The severity of ED was classified into five categories using EF in each age group. The univariate logistic regression analysis and multiple variate analysis of IIEF in HD patients were performed. The prevalence of ED in HD patients was significantly higher than that in the controls in each age group. The severity of ED in HD patients was also significantly higher than that in the controls in each age group. In the logistic regression analysis and multiple variate analysis of IIEF in HD patients, DM and age were significant risk factors on sexual dysfunction. ED was more prevalent in male renal failure patients treated with HD than in the controls. In the patient group, ED was more prevalent in older DM patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Significant decrease of the International Index of Erectile Function in male renal failure patients treated with hemodialysis

et al. 2002

View full text Add to dashboard Cite

show abstract

“…Anemia may be a contributing factor for ED 29 and use of recombinant human erythropoietin may provide some benefits over sexual functions of the patients with CKD. 30 In the study, group 1 had lower levels of hemoglobin than groups 2 and 3.…”

Section: Discussionmentioning

confidence: 99%

“…The degree of ED was divided into five categories: no ED (scores of [26][27][28][29][30], mild (scores of [22][23][24][25], mild-to-moderate (scores of 17-21), moderate (scores of [11][12][13][14][15][16], and severe (scores of 6-10). 12 Groups were composed as follows: group1: patients with CKD and ED; group 2: patients with CKD without ED; group 3: control patients without CKD or ED.…”

Section: Methodsmentioning

confidence: 99%

Effect of ADMA levels on severity of erectile dysfunction in chronic kidney disease and other risk factors

Gökçen

Kılıçarslan

Çoşkun

et al. 2016

CUAJ

View full text Add to dashboard Cite

Introduction: Hormonal, neurogenic, vasculogenic, and psychogenic impairments, as well as endothelial dysfunction may play a role in erectile dysfunction (ED) in patients with chronic kidney disease (CKD). Asymmetrical dimethylarginine (ADMA) is an inhibitor of nitric oxide, which is the key element of ED. ADMA levels are increased in CKD. We aimed to evaluate the effect of serum ADMA, prolactin, testosterone, and hemoglobin levels on erectile function of patients with CKD and control subjects. Methods: A total of 42 men with CKD and 25 age-matched controls were enrolled. The patients with CKD were categorized into group 1 and group 2 based on whether they had ED according to their response to International Index of Erectile Function questionnaire (IIEF-EFD). Group 3 was a control group. Serum ADMA, total testosterone prolactin, and hemoglobin levels of the patients were evaluated. Results: Serum ADMA, testosterone, and hemoglobin levels were similar between group 1 and 2, serum prolactin level was significantly high in group 1 than in group 2 or 3 (control group). There was no correlation between ADMA levels and IIEF-EFD scores of patients with CKD. Conclusions:The results of this study suggest serum ADMA level is not related with ED in patients with CKD. Also, low testosterone and hemoglobin levels were not significant factors. High levels of serum prolactin are related with ED in patients with CKD.

show abstract

“…Patients in dialysis complaining of sexual dysfunction after correction of anemia with rHuEpo were characterized by higher levels of serum testosterone, but not by suppression of hyperprolactinemia or hyperestrogenism (16) . We observed that the median serum prolactin was high in both HD groups with lack of a significant difference between them.…”

Section: Hormonal Profilementioning

confidence: 95%

“…However, this effect of rHuEpo on patients undergoing hemodialysis was not uniformly present (3,16,32) . Plasma concentration of LH was elevated in patients on maintenance hemodialysis, and the increase is thought to result from diminished release of testosterone from Leydig cells and decreased LH renal clearance (18) .…”

Section: Hormonal Profilementioning

confidence: 99%

Serum zinc and hormonal profile in male dialysis patients receiving human recombinant erythropoietin

Schleicher¹,

Moura²,

Diniz³

et al. 2005

J. Bras. Patol. Med. Lab.

View full text Add to dashboard Cite

Erythropoietin and sexual dysfunction

Cited by 52 publications

References 0 publications

Significant decrease of the International Index of Erectile Function in male renal failure patients treated with hemodialysis

Significant decrease of the International Index of Erectile Function in male renal failure patients treated with hemodialysis

Effect of ADMA levels on severity of erectile dysfunction in chronic kidney disease and other risk factors

Serum zinc and hormonal profile in male dialysis patients receiving human recombinant erythropoietin

Contact Info

Product

Resources

About